💊 AbbVie beats expectations: shares rise thanks to strong results and optimistic outlook! 🚀
Shares of biotech giant AbbVie $ABBV are up more than 4 %, after announcing better-than-expected quarterly earnings while raising its long-term outlook. Sales of Skyrizi and Rinvoq were a key driver of growth , offsetting declines in the once-flagship drug Humira.
What do you think of the current share price of $CAT?
The company reported results on Thursday that weren't bad, but the stock subsequently fell 5%. I was buying the stock at the end of 2023, and it has risen solidly since then, but the current price isn't bad, so I'm thinking of overbought.
📈 IBM surprises the market: Shares rise on strong results, AI expansion! 🤖💰
IBM $IBM also known as Pioneer of computer systems, released fourth-quarter results on Wednesday that beat Wall Streetexpectations and the stock responded by rising more than 10 %. 🚀
As for the quantum technology, IBM is doing well, but the question is whether the company can use it well and whether it will bring any money to the company.
☕ Starbucks: What direction will it take? 📉 Starbucks $SBUX may have slightly beaten Wall Street' s expectations and posted a better-than-expected quarterly profit, but it's also struggling with a decline in same-store sales - and for the fourth straight quarter. 📉
Do you also have shares of Czech banks in your portfolio?
Overall, Czech banks did well last year, with $MONET.PR up 30% and $ERBAG.PR up more than 60%. I bought $KOMB.PR and $ERBAG.PR last year for diversification and so far I am very satisfied.
💼 Microsoft, TikTok and billions in the game: Fighting for big business! 💰
Tech giant Microsoft $MSFT is considering a takeover of TikTok' s US operations . The whole thing came to light after an unexpected revelation by President Donald Trump, who mentioned the possibility while speaking to Republican lawmakers.
Trump even hinted at his preference for TikTok to be taken over by... Read more
Merck (MRK): a combination of innovation, growth potential and stable dividends
Merck $MRK continues to be a strong player in the pharmaceutical industry, despite the impending loss of patent protection on its flagship product Keytruda in 2028. Its innovation, portfolio expansion and stable dividend policy make it an attractive investment for long-term investors.
I'm not really into these drug companies. That's not to say that this or any other company is bad, on the contrary. Probably the closest I've come to investing in $CVS.
💊 AbbVie beats expectations: shares rise thanks to strong results and optimistic outlook! 🚀
Shares of biotech giant AbbVie $ABBV are up more than 4 %, after announcing better-than-expected quarterly earnings while raising its long-term outlook. Sales of Skyrizi and Rinvoq were a key driver of growth , offsetting declines in the once-flagship drug Humira.
...Read more
Zobrazit další komentáře
I don't like these stocks very much. The only stock I have from this sector is $NVO.
What do you think of the current share price of $CAT?
The company reported results on Thursday that weren't bad, but the stock subsequently fell 5%. I was buying the stock at the end of 2023, and it has risen solidly since then, but the current price isn't bad, so I'm thinking of overbought.
Zobrazit další komentáře
Society could profit quite a bit from the reconstruction of Ukraine in a few years, but I wouldn't bet on it.
📈 IBM surprises the market: Shares rise on strong results, AI expansion! 🤖💰
IBM $IBM also known as Pioneer of computer systems, released fourth-quarter results on Wednesday that beat Wall Streetexpectations and the stock responded by rising more than 10 %. 🚀
...Read more
Zobrazit další komentáře
As for the quantum technology, IBM is doing well, but the question is whether the company can use it well and whether it will bring any money to the company.
US carmakers face possible tariffs: Ford believes it is best prepared
Zobrazit další komentáře
In a word, great! 😄👍
Growth opportunities in the AI sector: two stocks to focus on according to Stifel
☕ Starbucks: What direction will it take? 📉
...Starbucks $SBUX may have slightly beaten Wall Street' s expectations and posted a better-than-expected quarterly profit, but it's also struggling with a decline in same-store sales - and for the fourth straight quarter. 📉
Read more
Zobrazit další komentáře
I have the stock in my portfolio and I'm in a pretty nice profit. Now after the results, it looks like the company should do well again.
Are you buying $MSFTstock or is it still expensive after today's -6%? 🤔
Zobrazit další komentáře
Microsoft is a great company, but I find Google much better. Google has a lot of projects lined up and the potential is much higher now.
Fertilisers that change the soil and the markets: the key to the future of agriculture
Trump and Meta have entered into an agreement to settle the lawsuit
Do you also have shares of Czech banks in your portfolio?
Overall, Czech banks did well last year, with $MONET.PR up 30% and $ERBAG.PR up more than 60%. I bought $KOMB.PR and $ERBAG.PR last year for diversification and so far I am very satisfied.
Zobrazit další komentáře
In addition to US banks, my portfolio includes $KOMB.PR. The stock is rising nicely right now and the dividend is pretty decent.
Analysts Believe Them: These 2 Growth Stocks Have Strong Buy Ratings
💼 Microsoft, TikTok and billions in the game: Fighting for big business! 💰
Tech giant Microsoft $MSFT is considering a takeover of TikTok' s US operations . The whole thing came to light after an unexpected revelation by President Donald Trump, who mentioned the possibility while speaking to Republican lawmakers.
Trump even hinted at his preference for TikTok to be taken over by...
Read more
Zobrazit další komentáře
I'm genuinely interested to see how this plays out and who ends up buying it. There are several companies, but Microsoft is one of the main ones.
Merck (MRK): a combination of innovation, growth potential and stable dividends
Merck $MRK continues to be a strong player in the pharmaceutical industry, despite the impending loss of patent protection on its flagship product Keytruda in 2028. Its innovation, portfolio expansion and stable dividend policy make it an attractive investment for long-term investors.
Keytruda: A...
Read more
Zobrazit další komentáře
I'm not really into these drug companies. That's not to say that this or any other company is bad, on the contrary. Probably the closest I've come to investing in $CVS.